“…Jeon et al [ 2 ] provides new insight into the mechanisms of rituximab resistance in DLBL and identifies a potential therapeutic strategy for overcoming this resistance. The authors developed a rituximab-resistant cell line (RRCL) by sequentially exposing cells to increasing concentrations of rituximab and then performed next-generation sequencing (NGS) to identify differences in gene expression between the RRCL and a rituximab-sensitive cell line.…”